My take is the Amarex issue is hindering the HIV a
Post# of 144106
Nothing in this PR states what's happening with NASH, TnBC, and other indications coming with the new CRO managing that data so I believe we will see a new focus.
A holdd on those two indications isn't a huge surprise with what's happened lately.
Let's be positive and see what the strategic direction that the board is driving and I believe things will fall in place when the timing is right.
We all know the FDA has been a bit less than fair to this company but such is life...